Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.62 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.62 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.53 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.53 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | CASP1 | P29466 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.49 |
| ▸ | DCLRE1B | Q9H816 | 1/20 | 0.48 |
| ▸ | HNF4A | P41235 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.46 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11464005 | 0.90 | CYP3A4 (0.62) | HPGDHSD17B10MEN1KMT2ACYP3A4 | |
| SCHEMBL28838076 | 0.87 | MEN1 (0.58) | HPGDHSD17B10MEN1KMT2ACYP3A4 | |
| SCHEMBL11537482 | 0.87 | CYP3A4 (0.58) | HPGDHSD17B10MEN1KMT2ACYP3A4 | |
| SCHEMBL6772376 | 0.82 | TSHR (0.69) | HSD17B10PTPN1PTPN2PTPN6TSHR | |
| SCHEMBL8961442 | 0.82 | PTPN1 (0.65) | PTPN1PTPN2PTPN6TSHRHNF4A | |
| SCHEMBL9440497 | 0.81 | PTPN1 (0.55) | MEN1KMT2APTPN1PTPN2PTPN6 | |
| SCHEMBL6441850 | 0.81 | PTPN1 (0.62) | ALOX15PTPN1PTPN2PTPN6TSHR | |
| SCHEMBL4905340 | 0.81 | TSHR (0.72) | HPGDHSD17B10MEN1KMT2ACYP3A4 | |
| SCHEMBL310681 | 0.81 | PTPN1 (0.58) | MEN1KMT2APTPN1PTPN2PTPN6 | |
| SCHEMBL3442800 | 0.80 | MEN1 (0.58) | HPGDHSD17B10MEN1KMT2ACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115646505-B | Method for preparing aminomethylbenzoic acid by catalytic oxidation of nano-carrier | 天和药业股份有限公司 | 2023-12-15 | — | — | CN | disclosed |
| CN-115646505-A | Method for preparing aminomethylbenzoic acid by catalytic oxidation of nano-carrier | 天和药业股份有限公司 | 2023-01-31 | — | — | CN | disclosed |
| US-8063098-B2 | GlyT1 receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2011-11-22 | — | — | US | disclosed |
| US-20110021540-A1 | Bis-(Sulfonylamino) Derivatives in Therapy 066 | ASTRAZENECA AB (SE) | 2011-01-27 | — | — | US | disclosed |
| CN-101910121-A | Bis (sulfonylamino) derivatives 066 in therapy | ASTRAZENECA AB | 2010-12-08 | — | — | CN | disclosed |
| EP-2217566-A1 | BIS-(SULFONYLAMINO) DERIVATIVES IN THERAPY 066 | AstraZeneca AB (SE) | 2010-08-18 | — | — | EP | disclosed |
| US-20100048531-A1 | GlyT1 RECEPTOR ANTAGONISTS | HOFFMANN-LA ROCHE, INC. | 2010-02-25 | — | — | US | disclosed |
| US-20090281138-A1 | Bis-(Sulfonylamino) Derivatives in Therapy 066 | ASTRAZENECA AB (SE) | 2009-11-12 | — | — | US | disclosed |
| WO-2009064250-A1 | BIS-(SULFONYLAMINO) DERIVATIVES IN THERAPY 065 | ASTRAZENECA AB (SE) | 2009-05-22 | — | — | WO | disclosed |
| WO-2009064251-A1 | BIS-(SULFONYLAMINO) DERIVATIVES IN THERAPY 066 | ASTRAZENECA AB (SE) | 2009-05-22 | — | — | WO | disclosed |
| US-4431823-A | SEDATIVES | HOFFMANN-LA ROCHE INC. (US) | 1984-02-14 | — | — | US | disclosed |
| US-4428879-A | SEDATIVES, TRANQUILIZERS | HOFFMANN-LA ROCHE INC. (US) | 1984-01-31 | — | — | US | disclosed |
| US-4428878-A | SEDATIVES, TRANQUILIZERS | HOFFMANN-LA ROCHE INC. (US) | 1984-01-31 | — | — | US | disclosed |
| EP-0094668-A2 | Pyrrole (3,4-d)(2)benzazepine derivatives | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1983-11-23 | — | — | EP | disclosed |
| US-4409390-A | 3-(2-AMINOETHYL)-4-(2-HYDROXYBENZYL-PHENYL) PYRROLE INTERMEDIATE | HOFFMANN-LA ROCHE INC. (US) | 1983-10-11 | — | — | US | disclosed |
| US-4405518-A | SEDATIVES | HOFFMANN-LA ROCHE INC. (US) | 1983-09-20 | — | — | US | disclosed |
| US-4379765-A | SEDATIVES, ANXIETY | HOFFMANN-LA ROCHE INC. (US) | 1983-04-12 | — | — | US | disclosed |
| US-4354973-A | SEDATIVES AND ANXIOLYTICS | HOFFMANN-LA ROCHE INC. (US) | 1982-10-19 | — | — | US | disclosed |
| EP-0045519-A2 | Pyrrolo-(3,4-d)-benzapines, process and intermediates for their preparation and pharmaceutical compositions containing them | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1982-02-10 | — | — | EP | disclosed |
| EP-0045521-A1 | Pyrazolobenzazepines, process for their preparation and pharmaceutical compositions containing them | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1982-02-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281138-A1 | Bis-(Sulfonylamino) Derivatives in Therapy 066 | CYP2D6, PTGER1, CYP2B6 | HPGD 232/4885HSD17B10 709/4885MEN1 2317/4885 |
| US-20100048531-A1 | GlyT1 RECEPTOR ANTAGONISTS | GLRA1, GLRA2, GRIA1 | HPGD 2184/4885HSD17B10 1205/4885MEN1 1701/4885 |
| US-20110021540-A1 | Bis-(Sulfonylamino) Derivatives in Therapy 066 | CYP2D6, PTGER1, CYP2B6 | HPGD 232/4885HSD17B10 709/4885MEN1 2317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.